A novel gene, pHyde, was recently cloned from Dunning rat prostate cancer cells. A recombinant adenovirus containing pHyde cDNA gene (AdpHyde) was generated to investigate the biological function of pHyde protein.
Introduction
Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer deaths in American men today with an estimated 198 100 new cases and 31 500 deaths predicted in year 2001 (Greenlee et al., 2001) . Like many carcinomas, prostate cancer formation is a multi-step process involving tumor initiation, promotion, transformation, and progression (Carter et al., 1990; Sandberg, 1992) . This process is driven by multiple factors including chromosomal instability, spontaneous mutations, and carcinogen-induced genetic and epigenetic changes.
While the involvement of several genes including IGF-1 (Mantzoros et al., 1997; Wolk et al., 1998) , DOC-2 (Tseng et al., 1998) , and pp32 (Kadkol et al., 1998) have been implicated in this process, the exact mutational events responsible for the multi-step progression of prostate cancer, however, are unknown. A better understanding of the molecular mechanisms responsible for prostate cancer may ultimately lead to new therapies. Therefore, identi®ca-tion and characterization of novel genes that may successfully inhibit or destroy prostate cancer cells may have potential utility in clinical application.
Using the improved cDNA competition hybridization technique, a novel cDNA designated as pHyde, was isolated and sequenced from cDNA libraries derived from two Dunning rat prostate cancer cell lines that have dierent metastatic phenotypes (Rinaldy and Steiner, 1999) . To characterize the novel gene pHyde, a replication-defective recombinant E1/E3 deleted adenovirus containing the rat pHyde cDNA gene (AdpHyde) was generated. Our previous studies showed that AdpHyde inhibited prostate cancer cell both in vitro and in vivo (Steiner et al., 2000) . Caspase-3 plays a critical role in the apoptotic signaling cascade (Cohen, 1997; , and its direct downstream target seems to be the caspaseactivated DNase (CAD) that induces the internucleosomal fragmentation of DNA Sakahira et al., 1998) . Speci®c inhibitors of caspase-3 such as DEVD (Okuma et al., 2000) and VAD (Okuma et al., 2000) block the activity of caspase-3 and suppress apoptosis (Hyer et al., 2000) . In this current study, pHyde is shown to be able to suppress prostate cancer by inducing caspase-3 mediated apoptosis.
Results

Adenoviral-mediated pHyde gene transfer results in protein expression
The isolated pHyde cDNA gene comprises of 2707 nucleotides with an open reading frame of 1467 nucleotides coding for a polypeptide of 488 amino acid residues (Figure 1) . To study the function of pHyde, a recombinant adenoviral vector containing pHyde gene under the control of RSV promoter (AdpHyde) was constructed. Human prostate DU145 tumors growing in nude mice were transduced by AdpHyde, and the tumor sections were analysed by immunohistochemistry employing an anti-pHyde antibody to assess and localize pHyde protein expression (Figure 2 ). Tumor sections exhibited pHyde protein along the injection-needle track of AdpHyde treated tumors (Figure 2b ), but not in control untreated tumors (Figure 2a ). The prostate cancer cells had both nuclear and cytoplasmic expression of pHyde protein (Figure 2b ). Thus, pHyde gene was transferred and pHyde protein was expressed in AdpHyde-transduced cells in vivo.
AdHyde inhibits cancer proliferation
Our previous study showed that AdpHyde (moi of 200) suppressed human prostate cancer DU145 cell growth in vitro (76% growth inhibition) (Steiner et al., 2000) . To determine whether the inhibitory eects of pHyde on prostate cancer cell growth was dose dependent, DU145 cells in culture were treated with AdpHyde, AdlacZ (control viral vector), and no virus in vitro at dierent moi levels. Cell growth was determined by counting the number of cells at 5 days after viral transduction. As shown in Figure 3 , AdpHyde signi®cantly inhibited the growth of DU145 cells when compared to controls: 49% inhibition at moi of 50, 71% inhibition at moi of 100, and 76.9% inhibition at moi of 200. Thus, AdpHyde appeared to inhibit prostate cancer cell proliferation in a dose dependent manner.
pHyde-mediated growth inhibition was also analysed in various other cancer cells. As shown in Table 1 , the majority of cancer cells tested were inhibited by pHyde. Interestingly, AdpHyde also inhibited human breast cancer MDA231 and MCF-7 cell growth, suggesting that pHyde has the ability to induce growth inhibition across dierent cell types.
pHyde induces apoptosis
Previous studies showed that pHyde caused DU145 cells to undergo apoptosis as demonstrated by the DNA fragmentation assay (Steiner et al., 2000) , thus suggesting that pHyde-mediated growth inhibition may involve apoptosis. To con®rm that pHyde does indeed induce apoptosis, AdpHyde transduced DU145 cells were subjected to the TUNEL assay 72 h after viral transduction. Bright yellow¯uores-cence-stained cells, representing cells undergoing apoptosis, were observed in AdpHyde transduced cells (Figure 4c ), whereas apoptotic cells were not signi®cantly seen in untreated control (Figure 4a ) or control virus transduced cells (Figure 4b ). Moreover, using nuclei staining agent DAPI, apoptosis was further con®rmed in AdpHyde transducd cells that underwent apoptosis with condensed and enlarged nuclei (Figure 4e ).
AdpHyde mediated apoptosis was also evaluated in vivo using the DU145 human xenograft prostate cancer tumor model. Tumor sections from DU145 tumors growing in nude mice showed that there was a signi®cant apoptosis (as indicated by bright yellowish¯uorescence-stained cells) following AdpHyde injection (Figure 5d ), compared to that of untreated tumors ( Figure 5c ) and control virus treated tumors (not shown). In addition, H&E stained tumor sections showed that AdpHyde treated DU145 tumors had areas of necrotic cells, degenerative changes, apoptotic bodies, and ®brosis ( Figure 5b ) compared to the untreated control tumors ( Figure  5a ).
To quantitate the relative proportion of the apoptotic population of the cells following AdpHyde transduction, AdpHyde transduced DU145 cells were analysed by¯ow cytometry following propidium iodide staining. As shown in Table 2 , the apoptotic population, as indicated by pre-G1 phase, was higher in AdpHyde transduced cells (13.23%) than observed for untreated (1.67%) and control virus transduced (3.68%) DU145 cells. Interestingly, both control virus and AdpHyde treated cells decreased population in G0/G1 phase and increased population in G2/M phase, though the exact reason needs to be investigated, it implies that adenovirus may promote cell division by stimulating cells to G2/M phases.
pHyde stimulated caspase-3 activity
Caspase-3 is a key apoptosis-signaling component whose direct downstream target is a CAD which induces the internucleosomal fragmentation of DNA Sakahira et al., 1998) . To determine whether pHyde-mediated apoptosis utilizes the caspase-3 signaling pathway, cell extracts from AdpHydetransduced DU145 cells were analysed for caspase-3 activity. pHyde stimulated a dose-dependent increase of caspase-3 activity by 48 h after viral transduction. AdpHyde (moi of 200) increased caspase-3 activity by 4.8-fold compared to untreated control cells, whereas the control virus (moi of 200) only had a minor increase of caspase-3 activity (1.6-fold compared to untreated control cells) (Figure 6a ). Stimulation of caspase-3 activity by pHyde was time dependent with the peak activity occurring 72 h following AdpHyde transduction. In contrast, untreated control cells and control virus transduced cells maintained a basal caspase-3 activity ( Figure 6b ).
Speci®c inhibitors of caspase-3 blocked pHydestimulated caspase-3 activity. As shown in Figure 7 , DU145 cells transduced with AdpHyde had 6.7-fold increase of caspase-3 activity compared to untreated control cells 72 h after viral transduction. However, pre-incubation of cells with 200 mM DEVD, a caspase-3 inhibitor, 24 h prior to viral transduction signi®cantly blocked pHyde-stimulated caspase-3 activity (only 1.3-fold increase compared to untreated control). Another caspase-3 inhibitor, 100 mM VAD, also suppressed caspase-3 activity. The concentrations of DEVE and VAD used in the experiments did not inhibit cell growth of untreated control DU145 cells (not shown). To further con®rm that caspase-3 stimulation was responsible for pHyde-mediated apoptosis, DU145 cells were pre-incubated with either 200 mM DEVD or 100 mM VAD 24 h prior to AdpHyde transduction. The concentration of caspase-3 inhibitor was maintained in the culture medium throughout the experiment. DNA was extracted from suspended cells 48 h after viral transduction and subjected to DNA fragmentation assay. DNA extracted from AdpHyde transduced cells exhibited a laddering pattern following electrophoresis in agarose gel (lane 4, Figure 8 ), a hallmark of cells undergoing apoptosis. In contrast, untreated control or control virus transduced cells did not have a laddering pattern (lanes 2 and 3, Figure 8 ). AdpHyde transduced cells which were pre-incubated with caspase-3 inhibitors, DEVD or VAD, however, showed reduction in DNA laddering (lanes 5 and 6, Figure 8 ), indicating that pHyde-mediated apoptosis was indeed blocked by caspase-3 inhibitors. Thus, the stimulation of caspase-3 activity was critical for the apoptotic induction by pHyde.
pHyde-mediated growth inhibition may require caspase-3
To determine whether caspase-3 is required for pHydemediated action, endogenous caspase-3 expression at protein level was screened in various cell lines. As shown in Figure 9 , PC-3 and MCF-7 cells had barely or no expression of caspase-3, and both cell lines showed either no or very low sensitivity to pHydemediated growth inhibition (Table 1) . These results suggest that pHyde-mediated growth inhibition may require caspase-3. On the other hand, expression of endogenous of caspase-3 alone may not be sucient enough to warrant an eective pHyde-mediated growth inhibition. Because TSU cells, which expressed a higher endogenous caspase-3 protein than that of DU145 cells (Figure 9 ), had a lower sensitivity to pHyde-mediated action (24.5% of growth inhibition by AdpHyde) than that of DU145 cells (76.5%) ( Table 1) . These results imply that caspase-3 is required for pHyde-mediated action but other cellular components are also required for an eective growth inhibition. 
Discussion
Apoptosis, the programmed cell death, is typically accompanied by the activation of a class of death proteases, caspases, and widespread biochemical and morphological changes to the cell (Nicholson and Thornberry, 1997; Porter et al., 1997) . Caspase-3 is a member of mammalian caspase family and serves as an apoptosis eector caspase (Chang and Yang, 2000) . The active caspase is generated by proteolytic processing at critical aspartic acids (Thornberry et al., 1992) . The eector procaspases are often activated by other proteases, most commonly by initiator caspases but also by other proteases. Procaspase-3 can be activated by caspase-8 and by granzyme B , an aspartic acid-speci®c serine protease that is an eector for cytotoxic T lymphocytes and natural killer cells mediated apoptosis (Talanian et al., 1997; Yang et al., 1998) . In addition, procaspase-3 can also be activated by short peptides containing the arginine-glycine-aspartate (RGD) motif (Buckley et al., 1999) . The direct downstream target of caspase-3 seems to be the inhibitor of CAD, the DNA endonuclease that cleaves chromosomal DNA and thus induces the DNA fragmentation Sakahira et al., 1998) . Caspase-3 cleaves and inactivates this inhibitor and thus releases active CAD that translocates into the nucleus where it degrades the DNA (Liu et al., 1997; Enari et al., 1998; Sakahira et al., 1998) . Recent studies showed that caspase-3 is essential for DNA fragmentation and morphological changes associated with apoptosis . Apoptosis is usually accompanied by the typical morphological changes and DNA fragmentation, however, apoptosis can also occur in the absence of DNA fragmentation (Ucker et al., 1992; Oberhammer et al., 1993; Schulze-Ostho et al., 1994; Sakahira et al., 1998) , implying that apoptosis can also be induced through a caspase-3 independent pathway. MCF-7 cells, which lack of caspase-3 activity due to a 47-bp deletion within exon 3 of the capase-3 gene (Janicke et al., 1998), can be induced to apoptosis without DNA fragmentation by apoptotic stimuli tumor necrosis factor (TNF) (Tewari et al., 1995; Duan et al., 1996; Janicke et al., 1996 Janicke et al., , 1998 , Fas (Tewari et al., 1995; Duan et al., 1996) , cytochrome c (Li et al., 1997) , staurosporine (Janicke et al., 1998), or by anti-estrogen agents tamoxifen and mifepristone (El-Etreby et al., 1998). Introduction of caspase-3 expression in MCF-7 cells showed DNA fragmentation and apoptosis-associated morphology in cells during TNF-induced apoptosis , indicating there are caspase-3 dependent and caspase-3 independent apoptotic pathways. Our previous study has shown that adenoviralmediated pHyde expression eectively inhibited prostate cancer growth both in vitro and in vivo through apoptotic induction (Steiner et al., 2000) . As a continuing study, this study has shown that caspase-3 is required for pHyde-mediated apoptosis. pHyde increased enzymatic activity of caspase-3 (Figure 6 ), and this elevated caspase-3 activity was blocked by DEVD and VAD, the inhibitors speci®c to caspase-3 (Figure 7 ), indicating that this pHyde-mediated elevation of caspase-3 activity is speci®c. Moreover, not only DEVD and VAD blocked elevated caspase-3 activity, they also blocked pHyde-mediated apoptosis (Figure 8) . Similarly, Fas ligand-induced apoptosis which involves caspase-3 was blocked by inhibitors speci®c to caspase-3 (Hyer et al., 2000) . A reverse relationship between endogenous caspase-3 expression and cell's susceptibility to pHyde-mediated action was observed: PC-3 and MCF-7, the cells which were not or barely sensitive to pHyde-mediated growth inhibition (Table 1 ) had no or barely expressed endogenous caspase-3 protein (Figure 9 ). These results taken Figure 6 pHyde stimulates caspase-3 enzymatic activity at a dose-and time-dependent manner. (a) Dose-dependent increase of caspase-3 activity by pHyde: DU145 cells were either untreated or transduced with control virus (moi of 200) or AdpHyde at various moi as indicated. The cells were harvested at 48 h after viral transduction and cell extracts were prepared and subjected to assay of caspase-3 activity as described in Materials and methods. The data represent average of the results from at least two independent experiments each performed in duplicate. The statistical analysis by student t-test showed that dierence between control virus treated and untreated control was statistically insigni®cant (P40.05), and dierences between AdpHyde treated and control virus treated (P50.01) as well as between AdpHyde treated and untreated control (P50.01) were statistically signi®cant for all the moi used. (b) Time-course of stimulated caspase-3 activity by pHyde: DU145 cells were transduced with control virus or AdpHyde at moi of 200, the cell extracts were prepared at various time points as indicated and subjected to assay of caspase-3 activity. The data represent average of the results from two independent experiments each performed in duplicate Figure 7 Caspase-3 inhibitors block the stimulated caspase-3 activity increased by pHyde. DU145 cells were treated with or without 200 mM DEVD or 100 mM VAD for 24 h prior to viral transduction and maintained at the same concentration throughout. The cells were then either untreated or transduced with AdpHyde at moi of 200 for 90 min. The cells were incubated for 72 h before harvesting. The activity of caspase-3 was measured as described in Figure 6 legend. The data represent average of the results from two independent experiments each performed in duplicate. The statistical analysis by student t-test showed that dierences between AdpHyde treated and control as well as between AdpHyde treated and AdpHyde plus DEVD (or VAD) treated were all statistically signi®cant (all P50.01) together suggest that pHyde mediates growth inhibition and apoptosis through a caspase-3 dependent pathway. It would be interesting to see whether MCF-7 cells expressing caspase-3 become more sensitive to pHyde-mediated growth inhibition.
Interestingly, the same cell line may have dierent sensitivities to dierent apoptosis-inducing agents. In our case, pHyde overexpression induced a signi®cant growth inhibition and apoptosis in LNCaP and DU145 cells, but had no eect on PC-3 cells (Table 1) . In contrast, apoptotic pathway induced by Fas ligand had a strong apoptosis eect in PC-3 cells, but had little and none eect on LNCaP and DU145 cells respectively (Rokhlin et al., 1997) . These results suggest that pHyde and Fas ligand have dierent apoptotic signaling pathways. In summary, this study shows that a novel gene pHyde has the ability to both suppress tumor growth and induce apoptosis through a caspase-3 dependent pathway. The growth inhibitory eect of pHyde was not limited in prostate cancer cells, for example, pHyde also suppressed human breast cancer cells, therefore, it suggests that pHyde may globally inhibit dierent tumor types. Therefore, characterization of this novel gene pHyde may have a therapeutic potential for cancer gene therapy application.
Materials and methods
Cell lines and tissue culture conditions
Human prostate cancer cell lines (obtained from ATCC, Rockville, MD, USA) DU145, LNCaP, TSU, and PC-3 were grown in RPMI-1640 medium (Cellgro, Herndon, VA, USA). Human breast cancer cell lines MDA231 and MCF-7 were grown in RPMI-164 and McCoy 5a medium respectively. Human embryonic kidney cell line 293 (ATCC) was grown in D-MEM medium (Cellgro). All cells were grown in medium containing 10% heat inactivated fetal bovine serum at 378C and 5% CO 2 .
Construction of recombinant adenoviruses
The construction of adenovirus containing rat pHyde cDNA under the control of Rous sarcoma virus (RSV) promoter, AdpHyde, was previously described (Steiner et al., 2000) . Single viral clones were propagated in 293 cells. The culture medium of the 293 cells showing the completed cytopathic eect was collected, and the adenovirus was puri®ed and concentrated by twice CsCl 2 gradient ultracentrifugation. The viral titration and transduction were performed as previously described (Graham and Prevec, 1991) . The control adenovirus, AdlacZ, in which an E. coli b-galactosidase reporter gene was placed under the control of RSV promoter, was generated by a similar way (Lu et al., 1999) .
Immunohistochemistry
To detect pHyde expression introduced by AdpHyde in vivo, xenograft tumors were established on nude mice. When tumors became palpable, a dose of 1610 10 pfu AdpHyde was directly injected into the tumor and the tumors were harvested 3 days later for immunohistochemical staining for pHyde protein expression. Tumor samples was paranembedded by a processor (model Citadel 2000, Shandon Inc., Pittsburgh, PA, USA) and sectioned by a microtome. The samples (slides) was ®rst incubated with 1% H 2 O 2 for 30 min. The rabbit anti-rat pHyde antibody was custommade by Research Genetics, Inc. (Huntsville, AL, USA) (Steiner et al., 2000) . The tumor sections were incubated with anti-pHyde antibody for 16 h at 48C, then by corresponding secondary antibodies and Universal Elite ABC Kit (Vector Laboratories, Inc., Burlingame, CA, USA) according to the manufacturer's protocol. The reaction was visualized with DAB solution (75 mg 3,3'-Diaminobenzidine and 30 ml 50% H 2 O 2 in 150 ml PBS) for 3 ± 10 min.
AdpHyde growth inhibition assay
Cancer cells were infected with control virus AdlacZ or AdpHyde in vitro with a multiplicity of infection (moi) of 200 or as indicated otherwise. After viral infection, cells were incubated at 378C and cell numbers were determined at days 5 to 7 after viral infection. Untreated cells were used as the control. In some cases, MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay was used instead of cell number counting. Brie¯y, the cells (1610 3 ) were plated on 96-well plate and incubated for 24 h. The cells were either untreated or transduced with control virus or AdpHyde. On the desired day post transduction, the cells were incubated with 5 mg/ml MTT for 4 h at 378C, then the cells were incubated with 10% SDS ± 5% isobutanol ± 0.12% HCl (w/v/v) for overnight at 37 C. The cell density was measured by a microplate reader at 550 nm.
TUNEL staining
For in vitro TUNEL assay, the slide¯asks (NUNC, Roskilde, Denmark) were precoated with 50 mg/ml poly-L-lysine (Sigma, St. Louis, MO, USA) for 15 min and washed twice with PBS. DU145 cells (1610 5 ) were plated on slide¯asks and grown for 24 h before viral transduction. The cells were then either untreated or transduced with control virus or AdpHyde at moi of 200. The cell monolayers grown on slides were rinsed twice with PBS at 72 h after transduction and subjected to TUNEL staining. For in vivo TUNEL assay, the xenograft DU145 tumors (untreated control tumors, control virus or AdpHyde treated tumors 52 days after a single dose of 5610 9 pfu intratumoral viral injection) growing in nude mice were harvested at necropsy, ®xed with freshly prepared 10% buered neutral formalin (Fisher Scienti®c, Fair Lawn, NJ, USA) overnight at room temperature, dehydrated in a gradual series of ethanol, and embedded in paran. Tissue sections were cut 4 mm thick, mounted on Superfrost Plus glass slides (Fisher, Scienti®c, Pittsburgh, PA, USA), deparanized with xylenes, rehydraded in a gradual series of ethanol, washed in H 2 O and subjected to TUNEL staining. Both in vitro and in vivo TUNEL assays use the In Situ Cell Death Detection Kit (Boehringer Mannheim, Indianapolis, IN) according to the manufacture's instruction. The TUNEL-stained cells were counter-stained with propidium iodide (Sigma, St. Louis, MO, USA) and visualized bȳ uorescence microscopy.
DAPI staining
The viral transduction and pretreatment of cells for DAPI staining are similar to those of TUNEL staining. The cell monolayers grown on slides were rinsed twice with PBS at 72 h after viral transduction. Then cells were ®xed with 4% paraformaldehyde (Merck, Darmstadt, Germany) solution (pH 7.4) for 30 min at room temperature, washed twice with PBS and stained with a 0.5 mg/ml solution of DAPI (Sigma, St Louis, MO, USA) in PBS for 10 min at room temperature. The slides were washed twice with PBS and visualized bȳ uorescence microscopy.
Flow cytometry to detect apoptotic population
Cells were arrested at G2/M phase by treating cells with 400 ng/ml nocodazole (Sigma) at 378C for 12 ± 16 h (Jackman and O'Connor, 1998) . After washing the cells, the synchronized cells were replated in fresh medium, and the cells were untreated or treated with viral transduction. Cellular DNA content that represents the cell cycle phase (G1, S, or G2/M) and apoptotic population (pre-G1) were detected by¯ow cytometry via determination of propidium iodide . After trypsinization, cells were washed with PBS and cell pellets were ®xed in 70% ethanol at 48C overnight. After being washed twice with PBS, the cells were stained with 50 mg/ml propidium iodide (Sigma, St. Louis, MO, USA), 10 mg/ml RNase A, 0.5% (v/v) Triton X-100 and 0.1% (w/v) sodium citrate for 30 min at room temperature in the dark followed by¯uorescent¯ow cytometry. The apoptotic population was de®ned by pre-G1 phase of the cell cycle.
In vitro measurement of caspase-3 protease activity
The activity of caspase-3 protease was measured in vitro using the Caspase-3 Cellular Activity Assay Kit PLUS (Biomol, Plymouth Meeting, PA, USA). Brie¯y, cells (1610 6 ) were plated on 10 cm dishes and grown for 24 h before viral transduction. The cells were then transduced with control virus or AdpHyde at moi=200 for 90 min. Culture medium was used for mock transduction for control. In some cases, DEVD or VAD (both from Biomol, Plymouth Meeting, PA, USA), the inhibitor of caspase-3 protease, were added either before or after viral transduction as indicated. The total cells including the¯oating and the attached were collected and prepared the cell extract at 48 h after transduction and subjected to detect the caspase-3 activity. Caspase-3 activity assay was according to the to the manufacture's instruction and read plate absorbance at 405 nm in a microplate-reader.
DNA extraction and gel electrophoretic analysis of DNA fragmentation
Soluble DNA was extracted as described previously (Oridate et al., 1996) . Brie¯y, the suspended cells in medium were collected 48 h post transduction by centrifugation. The pellet was resuspended in Tris-EDTA buer (pH 8.0). The cells were lysed in 10 mM Tris-HCl (pH 8.0), 10 mM EDTA, and 0.5% Triton X-100 on ice for 15 min. The lysate was centrifuged at 12 000 g for 15 min to separate soluble (fragmented) DNA from pelleted (intact genomic) DNA. Soluble DNA was treated with RNase A (50 mg/ml) at 378C for 1 h, followed by treatment with proteinase K (100 mg/ml) in 0.5% SDS, at 508C for 2 h. The residual material was extracted with phenol/chloroform, precipitated in ethanol, and electrophoresed on a 2% agarose gel.
Western blot
Cells were extracted and processed for gel electrophoresis as previously described (Lu et al., 1995) . Cell extract lysates (100 mg) were loaded on a 12% polyacrylamide gel and subjected to sodium dodecylsulfate (SDS) gel electrophoresis, then transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA, USA). The membrane was treated with blocking solution (15% nonfat milk, 0.02% sodium azide in phosphate-buered saline) overnight at 48C. The membrane was incubated for 1 h at room temperature with the primary antibody: rabbit anti-human caspase-3 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The membrane was then incubated for 1 h at room temperature with 125 I-labeled mouse anti-rabbit IgG (Amersham Life Science). To normalize the protein loading and transfer, the same membrane was incubated for 1 h at room temperature with the primary antibody: mouse anti-human actin antibody (Chemicon, Temecula, CA, USA). The membrane was then incubated for 1 h at room temperature with goat anti-mouse secondary antibody coupled to peroxidase (ECL Kit, Amersham Life Science), and performed ECL according to the Manufacturer's protocol.
